Have a personal or library account? Click to login
The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome Cover

The Role of Triglyceride to HDL Cholesterol Ratio in Sera as a Clinical Surrogate Marker for Cardiovascular Risk and Insulin Resistance in Patients with Metabolic Syndrome

Open Access
|Jan 2022

References

  1. 1. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva, Switzerland: World Health Organization; 1999:31–3.
  2. 2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.10.1001/jama.285.19.2486
  3. 3. International Diabetes Federation. The IDF Consensus Worldwide Definition of the Metabolic Syndrome. Brussels, Belgium: International Diabetes Federation; 2006.
  4. 4. Bluher M. Adipose tissue dysfunction in obesity. ExpClin Endocrinol Diabetes. 2009; 117:241-50.10.1055/s-0029-1192044
  5. 5. Karastegiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Molecular and Cellular Endocrinology. 2010;318:1784-92.
  6. 6. Leal VO, Mafra D. Adipokines in obesity. Clin Chim Acta. 2013;419:87–94.10.1016/j.cca.2013.02.003
  7. 7. Pereira S, Alvarez-Leite J. Adipokines: biological functions and metabolically healthy obese profile. J Receptor Ligand Channel Res. 2014;7:15-25.10.2147/JRLCR.S36060
  8. 8. Kwiterovich PO. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol. 2002;90:30–47.10.1016/S0002-9149(02)02749-2
  9. 9. Muniyappa R, Lee S, Chen H, Quon, MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008, 294:15-26.10.1152/ajpendo.00645.200717957034
  10. 10. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MBet al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000, 23:57-63.10.2337/diacare.23.1.5710857969
  11. 11. Miller WG, Thienpont LM, Van Uytfanghe K, Clark PM, Lindstedt P, Nilsson G et al. Insulin Standardization Work Group: Toward standardization of insulin immunoassays. Clin Chem. 2009, 55:1011-8.10.1373/clinchem.2008.11838019325009
  12. 12. McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, et al. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;96:399–404.
  13. 13. Liu A, Reaven GM. Is measurement of non-HDL cholesterol an effective way to identify the metabolic syndrome? Nutr Metab Cardiovasc Dis. 2013;23:1122–7.
  14. 14. Hadaegh F, Hatami M, Tohidi M, Sarbakhsh P, Saadat N, Azizi F. Lipid ratios and appropriate cut off values for prediction of diabetes: a cohort of Iranian men and women. Lipids Health Dis. 2010;9(1):1-9.10.1186/1476-511X-9-85293366520712907
  15. 15. Thomas G, Pickering, MD et al. Recomendation for blood pressure measurment in humans and experimental animals, Hypertension, 2004;45:142.
  16. 16. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Matthews et al. Diabetologia. 1985;28(7):412-9.10.1007/BF002808833899825
  17. 17. Matthews DR, Hosker JP, Rudenski AS еt al. Homeostasis model assessment: insulin resistance and beta-cells function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-41.10.1007/BF002808833899825
  18. 18. Da luz PL, Cesena FH, Favarato D, Cerqueira ES. Comparison of serumlipid values in patients with coronary artery disease at <50, 50 to 59, 60 to 69, and >70 years of age. Am J Cardiol. 2005;96:1640-3.10.1016/j.amjcard.2005.07.08016360350
  19. 19. Ke Wan, Jianxun Zhao, Hao Huang et al. The Association between Triglyceride/High-Density Lipoprotein Cholesterol Ratio and All-Cause Mortality in Acute Coronary Syndrome after Coronary Revascularization. 2015 Apr 16;10(4):e0123521.10.1371/journal.pone.0123521439984025880982
  20. 20. Thomas G, Pickering MD et al. Recomendation for blood pressure measurment in humans and experimental animals. Hypertension. 2004;45:142.
  21. 21. Matthews DR, Hosker JP, Rudenski AS еt al. Homeostasis model assessment: insulin resistance and beta-cells function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-41.10.1007/BF00280883
  22. 22. Ke Wan, Jianxun Zhao, Hao Huang et al. The Association between Triglyceride/High-Density Lipoprotein Cholesterol Ratio and All-Cause Mortality in Acute Coronary Syndrome after Coronary Revascularization. 2015 Apr 16;10(4):e0123521.10.1371/journal.pone.0123521
  23. 23. Koleva D, Orbetzova M. Metabolic and Atherogenic Parameters in Women with Metabolic Syndrome and MetabolicallyHealthy Overweight/Obese Women. Endocrinologia. 2017;2:81-6.
  24. 24. Naidenova, G. The АРО B/АРО A1 ratio in determinig the balance between plasma proatherogenic and anti-atherogenic lipoproteins. Medinfo. 2014;1. (In Bulgarian)
  25. 25. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are Insulin Resistant. Ann Internal Med. 2003;139(10):802-9.10.7326/0003-4819-139-10-200311180-0000714623617
  26. 26. Li C, Ford E, Meng Y, Mokdad A and Reaven G. Does the association of the triglyceride to high-density lipoprotein cholesterol ratio with fasting serum insulin differ by race/ethnicity? Cardiovascdiabetol. 2008; 7:4-10.
  27. 27. Sumner AE, Harman JL, Buxbaum SG, Miller BV, Tambay AV, Wyatt SB et al. The triglyceride/high-density lipoprotein cholesterol ratio fails to predict insulin resistance in African-American women: an analysis of Jackson Heart Study. MetabSyndrRelatDisord, 2010, 8:511-4.10.1089/met.2010.0028312556420715971
  28. 28. Jui-Chiang K, Lai N, Chang J, and Koo M. Predicting insulin resistance using the triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults. Cardiovasc Diabetol. 2011;10:93.10.1186/1475-2840-10-93322445422004541
  29. 29. Simi A, Tsakiri N, Wang P, Rothwell NJ. Interleukin-1 and inflammatory neurodegeneration. Biochemical Society Transactions. 2007;35(5):1122–6.10.1042/BST035112217956293
  30. 30. Fried SK, Bunkin DA & Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 1998;83:847–50.
  31. 31. Kang YE, Kim JM, Joung KH et al. The roles of adipokines, proinflammatory cytokines, and adipose tissue macrophages in obesity-Associated insulin resistance in modest obesity and early metabolic dysfunction. PLoS ONE. 2016;11:e0154003.10.1371/journal.pone.0154003483962027101398
  32. 32. Winkler G, Kiss S, Keszthelyi L, et al. Expression of tumor necrosis factor (TNF)-alphaprotein in the subcutaneous and visceral adipose tissue incorrelation with adipocyte cell volume, serum TNF-alpha, soluble serumTNF-receptor-2 concentrations and C-peptide level. Eur J Endocrinol. 2000;149:129–35.
  33. 33. Festa A, D‘Agostino R, Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102:42–7.10.1161/01.CIR.102.1.42
Language: English
Page range: 162 - 168
Submitted on: Jan 28, 2021
|
Accepted on: Jul 8, 2021
|
Published on: Jan 18, 2022
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2022 Silviya S. Ganeva, Ginka H. Rayanova, Katya N. Todorova, Tzvetan H. Lukanov, Svetla O. Blazheva, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.